MAGNESIUM-CONTAINING DRUGS IN CARDIOVASCULAR DISEASES
https://doi.org/10.20996/1819-6446-2012-8-3-463-468
Abstract
At present experimental and clinical data confirming efficacy of magnesium-containing drugs in different cardiovascular diseases are obtained. Physiological significance of magnesium is determined by its intracellular fraction. That is why it is desirable to use magnesium with the components contributing to its intracellular penetration. Magnerot deserves attention as a complex drug consisting of magnesium and orotic acid that contributes to intracellular penetration. Data of some studies on magnesium-containing drugs application in different cardiovascular diseases are presented.
About the Authors
A. V. Govorin
Chita State Medical Academy
Russian Federation
Russian Federation
A. P. Filev
Chita State Medical Academy
Russian Federation
Russian Federation
References
1. Kudrin A.V. Trans elements and apoptosis. J Trans Element Med Biol 1998; 12: 65–76.
2. Rardon D.P., Fisch C. Electrolytes and the Heart. In Hurst JW, ed. Hurst's the heart, 7th ed. New York: McGraw-Hill; 1990.
3. Agadzhanyan N.A., Tsirkin V.I., eds. Human Physiology. St. Petersburg: Sotis; 1998. Russian (Ага-джанян Н.А., Циркин В.И., редакторы. Физиология человека. СПб.: Сотис; 1998).
4. Liao F., Folsom A., Brancati F. Is low magnesium concentration a risk factor for coronary heart disease? The Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J 1998; 136 (3): 480–490.
5. Maier J.A. Low magnesium and atherosclerosis: an evidence-based. Molecular Aspects of Medicine 2003; 24: 3–9.
6. Shechter M., Sharir M., Labrador M. et al. Oral magnesium therapy improves endothelial function in patients with coronary artery disease. Circulation 2000; 102: 2353–2358.
7. Zehender M., Meinertz T., Just H. Magnesium deficiency and magnesium substitution. Effect on ventricular cardiac arrhythmias of various etiology. Herz 1997; 22 (1): 56–62.
8. Head K.A. Peripheral neuropathy: pathogenic mechanisms and alternative therapies. Altern Med Rev 2006; 11(4): 294–9.
9. Ma B., Lawson A.B., Liese A.D. et al. Dairy, magnesium, and calcium intake in relation to insulin sensitivity: approaches to modeling a dosedependent association. Am J Epidemiol 2006; 164(5): 449–58.
10. Rosenfeldt F. Metabolic supplementation with orotic acid and magnesium orotate. Cardiovasc Drugs Ther 1998; 12 (2): 147–152.
11. Bourre J. Effects of nutrients (in food) on the structure and function of the nervous system: update on dietary requirements for brain. Part 1: micronutrients. J Nutr Health Aging 2006; 10 (5): 377– 385.
12. Jellinek H., Takacs E. Morphological aspects of the effects of orotic acid and magnesium orotate on hypercholesterolemia in rabbits. Arzneimittelforschung 1995; 45 (8): 836–842.
13. Sueta C., Clarke S., Dunlap S. Effect of acute magnesium administration on the frequency of ventricular arrhythmia in patients with heart failure. Circulation 1994; 89: 660–666.
14. Iezhitsa I. Potassium and magnesium depletions in congestive heart ailurepathophysiology, consequences and replenishment. Clin Calcium 2005; 15(11): 123–133.
15. Etienne Y., Blanc J., Boschat J. et al. Anti-arrhythmic effects of intravenous magnesium sulfate in paroxysmal supraventricular tachycardia. Am Cardiol Angeiol 1988; 37 (9): 535–538.
16. Shilov A. M. Application of magnesium products for the prevention of cardiac arrhythmias in patients with acute myocardial infarction. Rosiyskiy Kardiologicheskiy Zhurnal 2002; (1): 16–19. Russian (Шилов А. М. Применение препаратов магния для профилактики нарушений ритма сердца у больных острым инфарктом миокарда. Российский Кардиологический Журнал 2002; (1): 16–19).
17. Shechter M. Does magnesium have a role in the treatment of patients with coronary artery disease? Am J Cardiovasc Drugs 2003; 3 (4): 231–239.
18. Hoshino K., Ogawa K., Hishitani T. et al. Successful uses of magnesium sulfate for torsades de pointes in children with long QT syndrome. Pediatr Int 2006; 48 (2): 112–117.
19. Therapy magnezium orotate. Tablets Magnerot. The scientific review. Moscow: Medpraktika; 2001. Russian (Терапия магнезиум оротатом. Таблетки Магнерот. Научный обзор. М.: Мед-практика; 2001).
20. Liao F., Folsom A.R., Brancati F.L. Is Low Magnesium Concentration a Risk Factor for Coronary Heart Disease? The Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J 1998; 136: 480–490.
21. Roberts D., Buckley N. Antidotes for acute cardenolide (cardiac glycoside) poisoning. Cochrane Database Syst Rev 2006; 18 (4): CD005490.
22. Petroianu A., Barquete J., Plentz E. Acute effects of alcohol ingestion on the human serum concentrations of calcium and magnesium. J Int Med Res 1991; 19 (5): 410–413.
23. Camm A., Janse M., Roden D. et al. Congenital and acquired long QT syndrome. Eur Heart J 2000; 21 (15): 1232–1237.
24. Pogorelko O.I., Orlov V.A., Shut'ko V.Yu. et al. Use of the drug in the treatment of Magnerot coronary heart disease patients with metabolic cardiovascular syndrome. Aktual'nye voprosy klinicheskoy zhelezno-dorozhnoy meditsiny: sbornik TsKB MPS 2000; 5: 223–233. Russian (Погорелко О.И., Орлов В.А., Шутько В.Ю. и др. Применение препарата Магнерот в терапии больных ишемической болезнью сердца с метаболическим кардиоваскулярным синдромом. Актуальные вопросы клинической железнодорожной медицины: сборник ЦКБ МПС 2000; 5: 223–233).
25. Woods K., Fletcher S., Roffe C. et al. Intravenous magnesium sulphate in suspected acute myocardial infarction: results of the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2). Lancet 1992; 339: 1553–1558.
26. Diaz R., Paolasso E. C., Piegas L. S. et al. on behalf of the ECLA (Estudios Cardiologicos Latinoamerica) collaborative group. Metabolic modulation of acute myocardial infarction. The ECLA glucose-insulin-potassium pilot trial. Circulation 1998; 98: 2227–2234.
27. Fath-Ordoubadi F., Beatt K. J. Glucose-insulin-potassium therapy for treatment of acute myocardial infarction. An overview of randomized placebo — controlled trials. Circulation 1997; 96: 1152– 1156.
28. Shechter M., Hod H., Chouraqui P. et al. Magnesium therapy in acute myocardial infarction when patients are not candidates for thrombolytic therapy. Am J Cardiol 1995; 75: 321–323.
29. Classen H. Magnesium orotate-experimental and clinical evidence. Rom J Intern Med 2004; 42 (3): 491–501.
30. Ueshima K. Magnesium and ischemic heart disease: a review of epidemiological, experimental, and clinical evidences. Magnes Res 2005; 18 (4):275–284.
31. Hadj A., Pepe S., Marasco S. et al. The principles of metabolic therapy for heart disease. Heart Lung Circ 2003; 12 (2): 55–62.
32. Witte K., Clark A. Micronutrients and their upplementation in chronic cardiac failure. An update beyond theoretical perspectives. Heart Fail Rev 2006; 11 (1): 65–74.
33. Lazebnik L.B., Drozdova S.L. Correction of magnesium deficiency in cardiovascular disease. Kardiologiia 1997; (5): 103–104. Russian (Лазебник Л.Б., Дроздова С.Л. Коррекция магниевого дефицита при сердечно-сосудистой патологии. Кардиология 1997; (5): 103–104).
34. Ostroumova O.D., Mel'nik O.O., Stepura O.B. Mitral valve prolapse – a norm or pathology? Russkiy Meditsinskiy Zhurnal 2002; 10(28): 1314–28. Russian (Остроумова О.Д., Мельник О.О., Степура О.Б. Пролапс митрального клапана — норма или патология? Русский Медицинский Журнал 2002; 10(28): 1314–28).
35. Geleijnse J.M., Witteman J.C., Bak A.A. et al. Reduction in blood pressure with a low sodium, high potassium, high magnesium salt in older subjects with mild to moderate hypertension. BMJ 1994; 309 (6952): 436–40.
36. Wirell M. P., Wester P. O., Segmayer B. J. Nutritional dose of magnesium in hypertensive patients on beta blockers lowers systolic blood pressure: a double-blind, cross-over study. J Intern Med 1994; 236: 189–195.
37. Minerals. In Drug Facts and Comparisons. St. Louis, MO: Facts and Comparisons; 2000:27-51.
Review
For citations:
Govorin A.V., Filev A.P. MAGNESIUM-CONTAINING DRUGS IN CARDIOVASCULAR DISEASES. Rational Pharmacotherapy in Cardiology. 2012;8(3):463-468. (In Russ.) https://doi.org/10.20996/1819-6446-2012-8-3-463-468
Views:
1306
Email this article 